Report
Hyloris Valacyclovir oral suspension deal with Rosemont, appoints new CFO
Hyloris announced an exclusive license and supply agreement with Rosemont Pharmaceuticals for its Valacyclovir oral suspension in the US. In addition, the company appointed a new CFO, Christophe Maréchal, who previously served as CFO and co-CEO of Mithra. We reiterate our € 5 TP and HOLD rating.
Underlying
Hyloris Pharmaceuticals
Provider
KBC Securities
We are a financial services provider for several types of professional clients, each with distinct needs.
Jacob Mekhael
Other Reports on these Companies
Other Reports from KBC Securities
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.